Di et al. found that isoleucyl-tRNA synthetase 2 (IARS2) acted as an oncogene in NSCLC by activating the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway (Di et al., 2019). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.